Vir Biotechnology (VIR) shares were trading at $11.09 with a P/E of 5.92 and hold $781 million in cash as they work toward critical data releases.

Vir Biotechnology, Inc. (VIR) shares were trading at $11.09 as of April 20th, with a trailing P/E ratio of 5.92. The company is focusing on Chronic Hepatitis Delta (HDV) and its oncology platform, with Phase 2 data indicating a 77% Target Not Detected (TND) rate. Regulatory uncertainties could affect their 2027 BLA timeline. Financially, VIR holds $781 million in cash, providing a runway into late 2027, although dilution risks exist ahead of key data releases in Q1 2027, which could significantly impact valuation.

Vir Biotechnology (VIR) Trading at $11.09 and P/E Ratio of 5.92

AI Summary

Related News

NIKE (NKE) Stock Analysis: P/E Ratio 30.58 with Current Value at $46.48

Airbnb (ABNB) Stock Analysis: Key Insights on Buy Potential

U.S. Bancorp (USB) Maintains Strong P/E Ratio at 11.95 and 11.34

Western Alliance Bancorporation (WAL) Evaluates Strong Valuation Metrics